Med Life SA

As of June 30, 2026, Med Life SA carries a market capitalization of 6.30B, placing it among publicly traded companies globally. Its enterprise value stands at 8.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Med Life SA's next confirmed earnings release is scheduled for November 20, 2026.

As of June 30, 2026, Med Life SA has 530.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.89, and the price-to-book ratio stands at 13.76.

As of June 30, 2026, Med Life SA trades at an EV/EBITDA multiple of 17.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 50.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.28B versus a market cap of 6.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Med Life SA maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 394.47, indicating elevated leverage, while an interest coverage ratio of 4.75 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Med Life SA posted a negative return on equity (ROE) of -8.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.13, reflecting losses generated across the asset base. The company generates approximately 449,515.68 in revenue per employee across its workforce of 7,393.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.31 indicates how many times Med Life SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Med Life SA recorded 23.53M in income tax expense. The company reported a pretax loss of -28.12M and -36.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Med Life SA's stock has gained approximately 37.07% over the past 52 weeks. The 50-day moving average sits at 10.94, while the 200-day moving average is 11.83.

Over the twelve months ended June 30, 2026, Med Life SA generated 3.32B in revenue and converted that into -36.49M in net income, yielding earnings per share of -0.10. EBITDA reached 467.28M, while operating income came in at 172.30M.

As of June 30, 2026, Med Life SA holds 158.58M in cash and equivalents against 2.07B in total debt, resulting in a net debt position of 1.49B. Total book value stands at 457.57M, with working capital of -206.96M providing operational flexibility.

Med Life SA produced 224.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -201.96M in capital expenditures, free cash flow totaled 22.46M - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Med Life SA posted a gross margin of 56.10, reflecting its pricing power and cost economics. The operating margin of 5.18 and net profit margin of -1.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.60, meaning Med Life SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Med Life SA's most recent stock split took place on September 1, 2023 with a 1:4 split ratio.

As of June 30, 2026, Med Life SA has an Altman Z-Score of 2.69, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.